Pharmaceutical companies from across the world along with government agencies have partnered to...
Coronavirus outbreak: Vaccines/drugs in the pipeline for Covid-19
Here are the potential human coronavirus vaccines/drugs pharmaceutical companies across the world are developing following the Wuhan coronavirus outbreak (Covid-19).
Zelira reports positive data from cannabis trial in insomnia
Australia-based Zelira Therapeutics has reported positive results from the Phase Ib/IIa clinical trial of cannabis drug candidate ZLT-101 in patients with chronic insomnia.
Alnylam closes enrolment in Phase III trial of vutrisiran
Alnylam Pharmaceuticals has completed patient enrolment in the Phase III HELIOS-A clinical trial of vutrisiran for the treatment of hereditary transthyretin (hATTR) amyloidosis.
Recardio to continue Phase II trial of dutogliptin
Life science company Recardio is set to continue the Phase II clinical trial of its dutogliptin drug in combination with filgrastim in severe heart attack patients.
China approves first anti-viral drug against coronavirus Covid-19
Anti-viral drug Favilavir has secured approval from the National Medical Products Administration of China to treat coronavirus Covid-19, according to media reports.
BMS reports Phase III data of Opdivo plus Yervoy in renal cancer
Bristol-Myers Squibb (BMS) has reported additional positive data from the Phase III CheckMate-214 clinical trial of Opdivo (nivolumab) in combination with Yervoy (ipilimumab) in patients with treatment-naïve advanced or metastatic renal cell carcinoma (RCC).
Covid-19: Pharmaceutical companies and agencies that partnered for coronavirus vaccine development
Pharmaceutical companies from across the world along with government agencies have partnered to develop a cure for the new coronavirus (Covid-19) that emerged from Wuhan, China.
ImmunogenX starts enrolment in Phase IIb celiac disease study
Biotherapeutics company ImmunogenX has commenced patient enrolment in a Phase IIb clinical trial of Latiglutenase (IMGX003) for the treatment of celiac disease.
Preclinical data of Gilead’s remdesivir raises hope for China trials
A study by the US National Institutes of Health (NIH) has demonstrated that Gilead’s antiviral drug, remdesivir, could prevent a type of coronavirus in monkeys.